Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 15Thoracic 5NET 4Genitourinary 3Gastrointestinal 3Dermatologic 3CNS 3Head & Neck 2Sarcoma 1Other 1Breast 1

Conditions

Obesity 373Neoplasms 134Breast Neoplasms 95Mucositis 94Overweight 91Sexual Dysfunction, Physiological 90Polycystic Ovary Syndrome 89Dyspnea 56Motor Activity 54Weight Loss 38Constipation 35Diabetes Mellitus 33Prostatic Neoplasms 32Head and Neck Neoplasms 30Colorectal Neoplasms 30Endometrial Neoplasms 26Lung Neoplasms 25Depression 25Diabetes Mellitus, Type 2 23Cardiovascular Diseases 23Multiple Endocrine Neoplasia Type 1 22Pain 20Anxiety Disorders 20Insulin Resistance 19Obesity, Morbid 18Pulmonary Disease, Chronic Obstructive 17Hypertension 17Sexual Dysfunctions, Psychological 16Metabolic Syndrome 16Colonic Neoplasms 16

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastrinoma × Other × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡